This indicates that permanent NRF2 activation may be a novel biomarker in lung cancers and that Nrf2 inhibitors may provide increased efficacy for the treatment of cancers in specific patients with abnormally high NRF2-ARE activation. This evidence concerns the gene NFE2L2 and cancer.